M&A Deal Summary

AXIM Biotech Acquires Sapphire Biotech

On January 8, 2020, AXIM Biotech acquired life science company Sapphire Biotech

Acquisition Highlights
  • This is AXIM Biotech’s 1st transaction in the Life Science sector.
  • This is AXIM Biotech’s 1st transaction in the United States.
  • This is AXIM Biotech’s 1st transaction in California.

M&A Deal Summary

Date 2020-01-08
Target Sapphire Biotech
Sector Life Science
Buyer(s) AXIM Biotech
Deal Type Add-on Acquisition

Target

Sapphire Biotech

San Diego, California, United States
Sapphire Biotech, Inc. is a research and development company that has a mission to improve global cancer care through the development of proprietary therapeutics for inhibiting cancer growth and metastasis. Sapphire is also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring.

Search 214,744 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

AXIM Biotech

San Diego, California, United States

Category Company
Founded 2010
Sector Life Science
Employees6
DESCRIPTION

AXIM Biotech focuses on the research, development, and production of cannabis-based pharmaceutical, nutraceutical, and cosmetic products. AXIM flagship products include CanChew Plus, a CBD-based controlled-release chewing gum containing 10mg of hemp-derived CBD, CanChew+ 50™, containing 50 mg of CBD undergoing clinical trials in patients with IBS, and MedChew Rx™, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. AXIM Biotechnologies was founded in 2010 and is based in San Diego, California.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2020 M&A 1 of 1